obesity drug news today glp-1 september 29 2025 New oral drugs could offer more options for weight loss Alarming rise in weight loss

While GLP-1 medications were originally developed for type 2 diabetes, they are now widely used to manage obesity and metabolic syndrome

G., Contreras, V., Menini, T., & Gugliucci, A

Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia Donghee Kang 1 , Dughyun Choi 2 Received August 8, 2025

Resmetirom: acts on the MASH and fibrosis regression by intrahepatic path Resmetirom is an orally administered, liver-targeted thyroid hormone receptor- (THR) selective agonist

doi: 10.1016/j.yhbeh.2019.104640 [DOI] [PubMed] [Google Scholar] 243